Shanghai Hegia Biomedicine

Hygieia Pharmaceuticals is a private Chinese biotech focused on RNA medicines and targeted delivery technologies, with a particular emphasis on siRNA therapeutics. The company states that it has built an end-to-end siRNA drug development platform spanning target discovery through proof-of-concept, and highlights proprietary delivery platforms including MVIP for bisite-conjugated GalNAc delivery, DDP for liver-origin diseases, and NSDP for neurological diseases. Its disclosed pipeline is concentrated in liver, cardiometabolic, complement-mediated, and neurological disorders, with Kylo-0603 emerging as the lead clinical asset. Kylo-0603 is a liver-targeted thyroid hormone receptor beta agonist being developed for MASH/NASH and has completed a Phase 1 healthy-volunteer study. The company appears to have evolved from a Shanghai identity to a Hangzhou registered entity while maintaining operations tied to Shanghai/Hangzhou biotech hubs.